What is Algorae Pharmaceuticals Operating Cash Flow per Share?
Algorae Pharmaceuticals's operating cash flow per share for the
six
months ended in Dec. 2023 was $0.00.
Algorae Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 41.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 27.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Algorae Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:
LVCLF'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -4.6 Med: 20.3 Max: 41.5
Current: 41.5
During the past 13 years, Algorae Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 41.50% per year. The lowest was -4.60% per year. And the median was 20.30% per year.
LVCLF's 3-Year OCF Growth Rate is ranked better than 86.79% of 1234
companies
in the Biotechnology industry
Industry Median: 3.45
vs LVCLF: 41.50
Algorae Pharmaceuticals Operating Cash Flow per Share Historical Data
The historical data trend for Algorae Pharmaceuticals's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Algorae Pharmaceuticals Operating Cash Flow per Share Chart
Competitive Comparison of Algorae Pharmaceuticals's Operating Cash Flow per Share
For the Biotechnology subindustry, Algorae Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Algorae Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Algorae Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Algorae Pharmaceuticals Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Algorae Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Jun. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Algorae Pharmaceuticals Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Algorae Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Algorae Pharmaceuticals (Algorae Pharmaceuticals) Business Description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LVCLF has been successfully added to your 